Resumen

IZQUIERDO CANO, Lissete M. et al. Use of Rituximab in recurrent chronic lymphocytic leukemia and autoimmune hemolytic anemia. A case presentation. Rev Cubana Hematol Inmunol Hemoter [online]. 2010, vol.26, n.2, pp. 77-81. ISSN 1561-2996.

The autoimmune hemolytic anemia is the more frequent immunologic manifestation in chronic lymphocytic leukemia (CLL) and it is present between 10-20 % of cases. Its prevalence is related to stage and progression of this blood disease, as well as to mutation state of genes from the heavy chain variable region of immunoglobulins. The corticosteroids are the first line treatment in this autoimmune hemolytic anemia, but only the third part of patients responds and achieves a lasting remission, whereas others require support treatment or of alternative type. Recently, it has been shown the effectiveness of Rituximab in treatment of refractory autoimmune hemolytic anemia that after 20months of ended this scheme it is maintained in complete remission.

Palabras clave : Rituximab; chronic lymphocytic leukemia; autoimmune hemolytic anemia.

        · resumen en Español     · texto en Español     · Español ( pdf )